AGEN logo

AGEN
Agenus Inc

12,477
Mkt Cap
$183.93M
Volume
827,402.00
52W High
$7.34
52W Low
$1.96
PE Ratio
-12.33
AGEN Fundamentals
Price
$4.79
Prev Close
$4.64
Open
$4.70
50D MA
$3.47
Beta
1.91
Avg. Volume
522,929.23
EPS (Annual)
-$0.0034
P/B
-0.62
Rev/Employee
$1.41M
$418.52
Loading...
Loading...
News
all
press releases
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating...
Business Wire·2d ago
News Placeholder
More News
News Placeholder
Will Declining Premiums & Higher MCR Weigh on MOH Q1 Earnings?
Molina Healthcare heads into Q1 earnings with falling estimates, weak membership trends, and rising MCR, casting doubt on a potential earnings beat.
Zacks·2d ago
News Placeholder
Will Robust Cardiovascular Performance Fuel BSX's Q1 Earnings?
Boston Scientific heads into Q1 earnings with strong Cardiovascular momentum and steady MedSurg growth, as estimates point to solid revenue and earnings gains.
Zacks·2d ago
News Placeholder
TGTX Completes Enrollment in Phase III Study on Subcutaneous Briumvi
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
Zacks·3d ago
News Placeholder
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
Zacks·3d ago
News Placeholder
Here's How Quest Diagnostics Is Placed Ahead of Q1 Earnings
DGX heads into Q1 earnings with steady growth expectations, but estimate cuts and a negative ESP could temper the outlook.
Zacks·4d ago
News Placeholder
Will Robust Medical Business Performance Fuel ABT's Q1 Earnings?
Abbott heads into Q1 earnings with solid Medical Devices and EPD growth, but Nutrition weakness and falling estimates cloud the outlook.
Zacks·4d ago
News Placeholder
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL treatment.
Zacks·5d ago
News Placeholder
Agenus (AGEN) is a Great Momentum Stock: Should You Buy?
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks·5d ago
News Placeholder
Agenus (NASDAQ:AGEN) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened
Agenus (NASDAQ:AGEN) Shares Pass Above 200-Day Moving Average - What's Next...
MarketBeat·5d ago
<
1
2
...
>

Latest AGEN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.